leadf
logo-loader
viewPreveCeutical Medical Inc.

PreveCeutical announces successful lab development of a cannabinoid Sol-Gel formulation to prevent or treat coronavirus

It cited two peer-reviewed papers reporting that high CBD strains could potentially have beneficial properties for the prevention/treatment of the SARS-CoV-2 infection, which causes the COVID-19 disease

cbd
PreveCeutical has successfully infused a high CBD strain into a proprietary Sol-Gel formulation, which is intended for self-administration using a Sol-Gel nasal spray device

PreveCeutical Medical Inc (CSE:PREV) (OTCQB:PRVCF) (FRA:18H) announced Wednesday the successful laboratory development of a cannabinoid Sol-Gel formulation (SARS-CoV-2 Sol-Gel) as a potential prevention and treatment for COVID-19. 

Independent scientific literature, the company noted, has reported that high CBD strains could potentially have beneficial properties for the prevention/treatment of the SARS-CoV-2 infection. 

PreveCeutical cited a peer-reviewed hypothesis paper titled, "The potential of cannabidiol in the COVID-19 pandemic," published in May by the British Journal of Pharmacology. There is a second article titled, "Cannabidiol Modulates Cytokine Storm in Acute Respiratory Distress Syndrome Induced by Simulated Viral Infection Using Synthetic RNA," published online in September.

READ: PreveCeutical files patent application in Australia seeking protection for cannabinoid formulations to prevent and treat COVID-19

PreveCeutical has successfully infused a high CBD strain into a proprietary Sol-Gel formulation, which is intended for self-administration using a Sol-Gel nasal spray device. This formulation is now ready for preclinical evaluation for pharmaceutical and nutraceutical applications.

The company also has filed a patent application to protect the intellectual property arising from the COVID-19 CBD Sol-Gel formulation.

"We are very pleased that a high CBD strain-specific Sol-Gel has been successfully formulated with the potential to address COVID-19,” said CEO Stephen Van Deventer in a statement.  

"The non-invasive, Sol-Gel delivery system, licensed from UniQuest Pty Ltd, is uniquely designed to deliver micelle loaded cannabinoids through trans-mucosal routes, rather than conventional oral routes. This delivery method will avoid hepatic metabolism and allow targeted delivery at the site of action. We will now move towards the start of preclinical assessment with the intention to rapidly move into the clinical trials process."

The company said it is not making any express or implied claims that its product has the ability to eliminate, cure, or contain COVID-19 at this time.

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

 

Quick facts: PreveCeutical Medical Inc.

Price: 0.03 CAD

CSE:PREV
Market: CSE
Market Cap: $14.76 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of PreveCeutical Medical Inc. named herein, including the promotion by the Company of PreveCeutical Medical Inc. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

PreveCeutical Medical announces completion on analgesic program is near

PreveCeutical Medical (CSE:PREV-OTCQB: PRVCF) CEO Stephen Van Deventer joined Steve Darling from Proactive Vancouver with news the company’s current stage of research for its disulfide linker technology will be completed soon. Van Deventer telling Proactive about the program and what the next...

on 23/7/20

2 min read